HACKENSACK, N.J., Jan. 2, 2014 (GLOBE NEWSWIRE) -- Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that its Baltimore, MD-based laboratory has received accreditation from The Joint Commission.
The Gold Seal of Approval™ from The Joint Commission was preceded by a rigorous inspection process. The approval upholds the exceptional level of patient care for Champions TumorGraft in vivo sensitivity testing platform.
"This is a significant achievement further validating the quality of our testing procedure" said Ronnie Morris, MD, president of Champions Oncology. "Not only does The Joint Commission accreditation confirm our high-level of clinical standards, but enables us to further grow our Personalized Oncology business."
In addition to The Joint Commission accreditation, Champions is also certified by the Clinical Laboratory Improvement Amendment ("CLIA") and has received approval from state departments of health, most recently the New York State Department of Health.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through its Personalized Oncology Solutions business.
This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2012 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.
CONTACT: Investor Relations Contact: Lauren Kwiecinski The Trout Group 646-378-2934 email@example.comSource:Champions Oncology